A pharmaceutical business developing novel.

The 12-month study may be the largest and longest potential nutritional and safety research ever completed for a pancreatic enzyme alternative therapy . Liprotamase can be a novel, oral, non-porcine PERT designed to treat maldigestion, malabsorption and malnutrition as a result of exocrine pancreatic insufficiency associated with CF, chronic pancreatitis , pancreatic cancer, pancreatectomy and additional pancreatic conditions. Findings from the open-label, Stage 3 long-term basic safety and nutritional study in patients with CF will become offered by Drucy Borowitz, M.D., Professor of Clinical Pediatrics, State University of NY at Buffalo, on Saturday, October 17, 2009 at 2:55 p.m.announced today that, at the mercy of market circumstances, it intends to provide $100 million principal amount of Convertible Senior Notes due 2016 . The Notes are being offered only to qualified institutional purchasers pursuant to Rule 144A beneath the Securities Action of 1933, as amended . In addition, Akorn intends to grant to the original purchasers of the Notes a 30-time over-allotment substitute for purchase up to yet another $20 million aggregate principal amount of the Notes. The Notes will be convertible into shares of Akorn’s common stock, cash, or a mixture thereof.